Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PYXS with free AI briefings, catalyst countdowns, and dilution alerts.

PYXS · Pyxis Oncology, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $1.41, 36% below $2.19, its close on the day of its Oct 1 underwritten offering. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$55.6M Cash on Hand
9.7mo Cash Runway
Follow PYXS by email Get an email when PYXS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PYXS, unsubscribe in one click. Privacy

📣 What PYXS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sotigalimab (APX005M) Melanoma Phase 1/2 · NCT02706353 Terminated
Micvotabart Pelidotin (PYX-201) Advanced Solid Tumors Phase 1/2 · NCT06795412 Recruiting
Aldastotug (PYX-106) Solid Tumor Phase 1 · NCT05718557 Active not recruiting

Also used in these trials (approved or third-party drugs, not PYXS's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PYXS holds $55.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $17.3M/quarter from operations, an estimated runway of 9.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 60 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PYXS files for a raise →

👥 Who Owns PYXS

Insiders 16.2% Other 5%+ holders 11.8% Institutions (110 holders) 58.8% Public and other holders 13.2%
HolderTypeShares% of sharesAs of
GordonMD Global Investments LP
10% owner · +7.17M options
Insider 15,541,909 12.99% 2026-10-01
BVF PARTNERS L P/IL Institution (13G, 5%+) 11,945,583 9.99% 2026-09-30
RTW Investments, LP Institution (13G, 5%+) 8,535,153 7.14% 2026-09-30
Lara Sullivan, M.D. 5%+ holder (13D) 7,543,007 6.31% 2025-03-31
Lara Sullivan 5%+ holder (13D) 6,624,699 5.54% 2024-12-23
Coastlands Capital LP Institution (13G, 5%+) 6,448,907 5.39% 2026-10-01
Laurion Capital Management LP Institution (13G, 5%+) 4,300,888 3.60% 2026-09-30
Pamela Ann Connealy
CFO & COO · +724,163 options
Insider 2,314,886 1.94% 2024-11-26
Jitendra Wadhane
Prin Fin & Acct Officer · +676,417 options
Insider 512,882 0.43% 2026-03-24
John L Flavin
Director · +82,846 options
Insider 413,015 0.35% 2024-03-26
Darren S Cline
Director · +82,846 options
Insider 251,405 0.21% 2024-03-26
Freda C Lewis-Hall
Director · +82,846 options
Insider 241,405 0.20% 2024-03-26

Share count 119,607,855 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PYXS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PYXS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.